Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TURNING POINT THERAPEUTICS, INC.

(TPTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
38.32(c) 38.06(c) 36.47(c) 38.8(c) 35.82(c) Last
284 989 351 410 706 350 638 831 732 718 Volume
-2.49% -0.68% -4.18% +6.39% -7.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 30,8 M - -
Net income 2021 -226 M - -
Net cash position 2021 968 M - -
P/E ratio 2021 -7,81x
Yield 2021 -
Sales 2022 5,32 M - -
Net income 2022 -311 M - -
Net cash position 2022 755 M - -
P/E ratio 2022 -5,77x
Yield 2022 -
Capitalization 1 772 M 1 772 M -
EV / Sales 2021 26,1x
EV / Sales 2022 191x
Nbr of Employees 237
Free-Float 96,3%
More Financials
Company
Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). Its drug discovery approach integrates tumor biology with structure-based drug... 
More about the company
Ratings of Turning Point Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about TURNING POINT THERAPEUTICS, INC.
11/10Turning Point Therapeutics to Participate in Upcoming Investor Conferences
GL
11/10Oppenheimer Adjusts Turning Point Therapeutics PT to $115 From $150, Maintains Outperfo..
MT
11/09TURNING POINT THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/09TURNING POINT THERAPEUTICS REPORTS THIRD-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONA..
PU
11/09TURNING POINT THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Con..
AQ
11/09Earnings Flash (TPTX) TURNING POINT THERAPEUTICS Reports Q3 Revenue $460,000
MT
11/09Turning Point Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nin..
CI
11/09Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operationa..
AQ
11/08Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President ..
GL
11/08Turning Point Therapeutics, Inc. Announces Executive Appointments
CI
11/02Turning Point Therapeutics to Host Third Quarter 2021 Conference Call
AQ
10/23TURNING POINT THERAPEUTICS : Presents Early Clinical Data for Repotrectinib From Care Stud..
AQ
10/13TURNING POINT THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
10/13TURNING POINT THERAPEUTICS : EQRx to Evaluate Elzovantinib Combo in Lung Cancer Trial -- S..
MT
10/13TURNING POINT THERAPEUTICS : and EQRx Announce Clinical Collaboration to Evaluate Elzovant..
GL
More news
News in other languages on TURNING POINT THERAPEUTICS, INC.
11/09Earnings Flash (TPTX) TURNING POINT THERAPEUTICS annonce un revenu de 460 000 $ pour le..
10/13Turning Point et EQRx vont évaluer le combo Elzovantinib dans le cadre d'un essai sur l..
10/11Les actions de Turning Point Therapeutics chutent après la rétrogradation de JMP Securi..
10/04Turning Point Therapeutics obtient de la FDA la désignation de thérapie innovante pour ..
08/16Turning Point Therapeutics lance une étude de phase 1b/2 sur l'association Repotrectini..
More news
Analyst Recommendations on TURNING POINT THERAPEUTICS, INC.
More recommendations
Chart TURNING POINT THERAPEUTICS, INC.
Duration : Period :
Turning Point Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TURNING POINT THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 35,82 $
Average target price 130,00 $
Spread / Average Target 263%
EPS Revisions
Managers and Directors
Athena Countouriotis President, Chief Executive Officer & Director
Paolo Tombesi Executive VP, Chief Financial & Accounting Officer
Mark J. Alles Chairman
Siegfried Reich Chief Scientific Officer & Executive VP
Mohammad Hirmand Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
TURNING POINT THERAPEUTICS, INC.-70.07%1 772
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819